Allergan PLC. (NYSE:AGN) was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report released on Wednesday, MarketBeat.com reports. They presently have a $228.00 price target on the stock, down from their prior price target of $284.00. Morgan Stanley’s price target indicates a potential upside of 8.57% from the stock’s previous close.

Several other analysts also recently weighed in on the stock. Deutsche Bank AG reiterated a “buy” rating and issued a $262.00 price objective on shares of Allergan PLC. in a research report on Tuesday, September 12th. Wells Fargo & Company reiterated an “outperform” rating on shares of Allergan PLC. in a research report on Monday, September 11th. Royal Bank Of Canada reiterated a “buy” rating and issued a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. Cantor Fitzgerald reiterated a “hold” rating on shares of Allergan PLC. in a research report on Tuesday, August 29th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $400.00 price objective on shares of Allergan PLC. in a research report on Tuesday, August 29th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $273.34.

Shares of Allergan PLC. (NYSE:AGN) traded down 2.33% on Wednesday, hitting $210.00. 5,474,505 shares of the stock were exchanged. The firm has a market cap of $70.20 billion, a price-to-earnings ratio of 6.40 and a beta of 1.18. The firm’s 50 day moving average price is $229.79 and its 200 day moving average price is $236.07. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period last year, the firm posted $3.35 EPS. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts anticipate that Allergan PLC. will post $16.25 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Allergan PLC. (AGN) Stock Rating Lowered by Morgan Stanley” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/20/allergan-plc-agn-stock-rating-lowered-by-morgan-stanley.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Intl Fcstone Inc. acquired a new position in shares of Allergan PLC. in the 2nd quarter worth approximately $1,626,000. Phocas Financial Corp. acquired a new position in shares of Allergan PLC. in the 2nd quarter worth approximately $150,000. Sentry Investment Management LLC grew its stake in shares of Allergan PLC. by 1.0% in the 2nd quarter. Sentry Investment Management LLC now owns 26,889 shares of the company’s stock worth $6,536,000 after purchasing an additional 265 shares during the last quarter. WFG Advisors LP grew its stake in shares of Allergan PLC. by 20.9% in the 2nd quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after purchasing an additional 137 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in shares of Allergan PLC. by 25.2% in the 2nd quarter. Toronto Dominion Bank now owns 113,770 shares of the company’s stock worth $27,651,000 after purchasing an additional 22,873 shares during the last quarter. 82.02% of the stock is currently owned by institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.